Floatz Rating
BB65/100
Confidence
Indicative
Sponsor
Cancer Research UK
Modality
Small molecule
Development Phase
Phase 2/3
Status
Active
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
65High confidence
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT07440290CT.gov DETERMINE Trial Treatment Arm 07: Dabrafenib in Combination With Trametinib in Adult, Paediatric and Teenage/Young Adult Patients With BRAF V600 Mutation-Positive Cancers. | — | Not Yet Recruiting | — | — | — |
NCT05275374CT.gov XP-102 and XP-102 in Combination With Trametinib in Advanced Solid Tumor Patients With a BRAF V600 Mutation | — | Not Yet Recruiting | — | — | — |
NCT06804824CT.gov A First-in-Human (FIH) Study to Evaluate the Safety and Tolerability of VVD-159642 in Participants With Advanced Solid Tumors | — | Recruiting | — | — | — |
NCT05988697CT.gov Evaluate the Efficacy and Safety of Aspirin in Combination With Trametinib and Dabrafenib | — | Not Yet Recruiting | — | — | — |
NCT05876806CT.gov Dabrafenib Plus Trametinib in Patients With Advanced Solid Tumor Having BRAF V600E Mutation or Clinically Actionable BRAF Gene Alterations | — | Unknown | — | — | — |
NCT05159245CT.gov The Finnish National Study to Facilitate Patient Access to Targeted Anti-cancer Drugs | — | Recruiting | — | — | — |
NCT05071183CT.gov A Study of Repotrectinib in Combination With Other Anticancer Therapies for the Treatment of Subjects With KRAS-Mutant Solid Tumors | — | Terminated | — | — | — |
NCT04892017CT.gov Study of Inlexisertib (DCC-3116) in Participants With RAS/MAPK Pathway Mutant Solid Tumors | — | Terminated | — | — | — |
NCT04185883CT.gov Sotorasib Activity in Subjects With Advanced Solid Tumors With KRAS p.G12C Mutation (CodeBreak 101) | — | Active Not Recruiting | — | — | — |
NCT03714958CT.gov Trametinib + HDM201 in CRC Patients With RAS/RAF Mutant and TP53 Wild-type Advanced/Metastatic Colorectal Cancer Mutant and TP53 Wild-type | — | Completed | — | — | — |
Show 30 more trialsShow fewer
NCT03543306CT.gov Dabrafenib and Trametinib in Patients With Non-small Cell Lung Cancer Harboring V600E BRAF Mutation | — | Unknown | — | — | — |
NCT02939846CT.gov Pharmacokinetics of Single and Repeat Oral Doses of Trametinib in Chinese Subjects With Solid Tumours | — | Withdrawn | — | — | — |
NCT02693535CT.gov TAPUR: Testing the Use of Food and Drug Administration (FDA) Approved Drugs That Target a Specific Abnormality in a Tumor Gene in People With Advanced Stage Cancer | — | Recruiting | — | — | — |
NCT02292732CT.gov A Pharmacokinetics (PK) and Safety Study to Determine the Effect of Repeat Dosing of Trametinib on Combined Oral Contraceptive (Norethindrone Plus Ethinyl Estradiol) in Female Subjects With Solid Tumors | — | Withdrawn | — | — | — |
NCT02110355CT.gov A Phase 1b/2a Study Evaluating AMG 232 in Metastatic Melanoma | — | Completed | — | — | — |
NCT02065063CT.gov A Study to Investigate the Safety, Pharmacokinetics, Pharmacodynamics, and Anti-Cancer Activity of Trametinib in Combination With Palbociclib in Subjects With Solid Tumors | — | Completed | — | — | — |
NCT02016729CT.gov A Phase 1b Study Evaluating AMG 232 Alone and in Combination With Trametinib in Acute Myeloid Leukemia | — | Completed | — | — | — |
NCT01989585CT.gov Testing the Addition of Navitoclax to the Combination of Dabrafenib and Trametinib in People Who Have BRAF Mutant Melanoma | — | Active Not Recruiting | — | — | — |
NCT02083354CT.gov Study to Investigate the Objective Response Rate of Dabrafenib in Combination With Trametinib in Subjects With BRAF V600 Mutation-Positive Melanoma | — | Completed | — | — | — |
NCT02034110CT.gov Efficacy and Safety of the Combination Therapy of Dabrafenib and Trametinib in Subjects With BRAF V600E- Mutated Rare Cancers | — | Completed | — | — | — |
NCT01938443CT.gov A Dose Escalation Study to Assess Safety of GSK2256098 (FAK Inhibitor) in Combination With Trametinib (MEK Inhibitor) in Subjects With Advanced Solid Tumors | — | Completed | — | — | — |
NCT01725100CT.gov A Study to Determine the Relative Bioavailability of the MEK Inhibitor, Trametinib, in Subjects With Solid Tumor Malignancies | — | Completed | — | — | — |
NCT01750918CT.gov BRAF/MEK/EGFR Inhibitor Combination Study in Colorectal Cancer (CRC) | — | Completed | — | — | — |
NCT01658553CT.gov A Study to Look at the Electrical Activity of the Heart in Subjects With Solid Tumor Cancers, Before and After Receiving the Study Treatment, GSK1120212 | — | Completed | — | — | — |
NCT01647659CT.gov Relative Bioavailibilty for Pediatric Powder for Suspension (PfOS) Formulation | — | Completed | — | — | — |
NCT01476137CT.gov A Study of the Safety and Activity of the MEK Inhibitor Given Together With the AKT Inhibitor to Patients With Multiple Myeloma or Solid Tumor Cancers | — | Completed | — | — | — |
NCT01336634CT.gov Study of Selective BRAF Kinase Inhibitor Dabrafenib Monotherapy Twice Daily and in Combination With Dabrafenib Twice Daily and Trametinib Once Daily in Combination Therapy in Subjects With BRAF V600E Mutation Positive Metastatic (Stage IV) Non-small Cell Lung Cancer. | — | Completed | — | — | — |
NCT01416337CT.gov Absolute Bioavialability of GSK1120212 | — | Completed | — | — | — |
NCT01371487CT.gov GSK1120212 Food-effect Study | — | Completed | — | — | — |
NCT00920140CT.gov Open-label Study to Evaluate the Safety, PK, and PD of MEK Inhibitor GSK1120212 in Subjects With Relapsed or Refractory Leukemias | — | Completed | — | — | — |
NCT01387204CT.gov Study to Investigate the Absorption, Distribution, Metabolism and Elimination of [14C]GSK1120212 | — | Completed | — | — | — |
NCT01248858CT.gov Study to Investigate the Safety, Pharmacokinetics, Pharmacodynamics, and Clinical Activity of GSK2126458 and GSK1120212 Combination Therapy in Subjects With Advanced Solid Tumors. | — | Terminated | — | — | — |
NCT01376310CT.gov GSK1120212 Rollover Study | — | Terminated | — | — | — |
NCT01328106CT.gov Efficacy and Safety Study of GSK1120212, a MEK Inhibitor, in Subjects With Uveal Melanoma | — | Withdrawn | — | — | — |
NCT01192165CT.gov Safety and Tolerability Study of GSK1120212, a MEK Inhibitor, in Combination With Docetaxel, Erlotinib, Pemetrexed, Pemetrexed + Carboplatin, Pemetrexed + Cisplatin, or Nab-Paclitaxel | — | Completed | — | — | — |
NCT01231581CT.gov Study of GSK1120212 Plus Gemcitabine vs Placebo Plus Gemcitabine in Metastatic Pancreatic Cancer | — | Completed | — | — | — |
NCT01138085CT.gov Safety, Pharmacokinetics (PK) of AKT and MEK Combination | — | Completed | — | — | — |
NCT01072175CT.gov Investigate Safety, Pharmacokinetics and Pharmacodynamics of GSK2118436 & GSK1120212 | — | Completed | — | — | — |
NCT01037127CT.gov Study to Determine the Effectiveness of GSK1120212 in BRAF Mutation-positive Melanoma Previously Treated With or Without a BRAF Inhibitor | — | Completed | — | — | — |
NCT00955773CT.gov A Study of the GSK MEK Inhibitor GSK1120212 and Everolimus in Cancer Subjects | — | Completed | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
65High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Cancer
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Trametinib (this asset) | Cancer Research UK | P2/3 | BB · 65 |
| Nabiximols | Jazz Pharmaceuticals | P3 | BBB |
| Pyridoxol | M.D. Anderson Cancer Center | P4 | BB |
| Rivoceranib | Jiangsu HengRui Medicine Co., Ltd. | P4 | BB |
| Desflurane | Peter MacCallum Cancer Centre, Australia | P4 | BB |
| Propofol | Hong Kong Children's Hospital | P4 | BB |
| Epirubicin | Zhejiang Provincial People's Hospital | P3 | BB |
| Atorvastatin | Cancer Institute and Hospital, Chinese Academy of Medical Sciences | P2/3 | BB |
| Anamorelin | Helsinn Healthcare SA | P3 | BB |
+42 more in the Cancer cohort
Other indications for Trametinib
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Melanoma | — | P4 | BB · 69 |
| Anaplastic Pleomorphic Xanthoastrocytoma | — | P4 | BB · 69 |
| Anaplastic Oligodendroglioma | — | P4 | BB · 69 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
Citation
Floatz Terminal. Trametinib in Cancer. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/trametinib-cancer
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →